Invalidity dossier
US 5661016
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
Current assignee: Genpharm International Inc
Added 9/23/2026, 10:04:59 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 5,661,016
Title: Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Patent number / application: US5661016A; application US08/053,131, filed 1993-04-26; granted and published 1997-08-26.
Assignee: Genpharm International Inc (original and current assignee as listed). Inventors: Nils Lonberg and Robert M. Kay.
Priority date: 1990-08-29 (the source notes the priority date is an assumption and not a legal conclusion). The record lists priority claims from several earlier applications, including US07/810,279 (1991-12-17), US07/834,539 (1992-02-05), US07/853,408 (1992-03-18), US07/990,860 (1992-12-16), and PCT/US1992/010983 (1992-12-17). Legal status is listed as "Expired – Lifetime"; the record notes an anticipated expiration on 2014-08-26. The source states that legal status and priority/assignee listings are assumptions, not legal conclusions or warranties of accuracy.
Purpose (plain language): According to the title and the listing of prior-art keywords (human, gene, immunoglobulin, segments, sequences), the patent concerns making transgenic non-human animals that carry human immunoglobulin gene sequences and can produce heterologous (human) antibodies, including antibodies of more than one isotype.
Scope (plain language): The claimed subject matter appears directed to such transgenic animals and the antibodies they produce of various isotypes. Classifications include A01K67/0275 (genetically modified vertebrates, e.g. transgenic), A01K67/0278 (knock-in vertebrates, e.g. humanised vertebrates), C12N15/87 and C12N15/90 (introduction of foreign genetic material; stable introduction of foreign DNA into chromosome), and C07K16/00 (immunoglobulins).
What the excerpt does not establish: The supplied text contains no claims, no written description, no examples, and no sequence listings. It therefore does not establish the precise claim scope, the specific immunoglobulin gene segments used, the animal species, or the mechanism by which multiple isotypes are produced.
Generated 10/1/2026, 9:33:46 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5661016. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.